Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE.

Pharmacol Rev. 2015 Oct;67(4):1005-24. doi: 10.1124/pr.114.010397. Review.

2.

A Single Amphetamine Infusion Reverses Deficits in Dopamine Nerve-Terminal Function Caused by a History of Cocaine Self-Administration.

Ferris MJ, Calipari ES, Rose JH, Siciliano CA, Sun H, Chen R, Jones SR.

Neuropsychopharmacology. 2015 Jul;40(8):1826-36. doi: 10.1038/npp.2015.45. Epub 2015 Feb 18.

3.

Agonist Medications for the Treatment of Cocaine Use Disorder.

Negus SS, Henningfield J.

Neuropsychopharmacology. 2015 Jul;40(8):1815-25. doi: 10.1038/npp.2014.322. Epub 2014 Dec 11. Review. No abstract available.

4.

Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining.

Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R.

Neuropsychopharmacology. 2014 Apr;39(5):1066-80. doi: 10.1038/npp.2013.307. Epub 2013 Oct 30.

5.

Amphetamine augments vesicular dopamine release in the dorsal and ventral striatum through different mechanisms.

Avelar AJ, Juliano SA, Garris PA.

J Neurochem. 2013 May;125(3):373-85. doi: 10.1111/jnc.12197. Epub 2013 Mar 6.

6.

Pharmacological characterization of designer cathinones in vitro.

Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME.

Br J Pharmacol. 2013 Jan;168(2):458-70. doi: 10.1111/j.1476-5381.2012.02145.x.

7.

Pharmacotherapy for attention-deficit/hyperactivity disorder: from cells to circuits.

Minzenberg MJ.

Neurotherapeutics. 2012 Jul;9(3):610-21. doi: 10.1007/s13311-012-0128-7. Review.

8.

4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2011 Nov;339(2):530-6. doi: 10.1124/jpet.111.184119. Epub 2011 Aug 2.

9.

High doses of amphetamine augment, rather than disrupt, exocytotic dopamine release in the dorsal and ventral striatum of the anesthetized rat.

Ramsson ES, Howard CD, Covey DP, Garris PA.

J Neurochem. 2011 Dec;119(6):1162-72. doi: 10.1111/j.1471-4159.2011.07407.x. Epub 2011 Aug 25.

10.

Amphetamine augments action potential-dependent dopaminergic signaling in the striatum in vivo.

Ramsson ES, Covey DP, Daberkow DP, Litherland MT, Juliano SA, Garris PA.

J Neurochem. 2011 Jun;117(6):937-48. doi: 10.1111/j.1471-4159.2011.07258.x. Epub 2011 May 3.

11.

Pharmacological approaches to methamphetamine dependence: a focused review.

Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL.

Br J Clin Pharmacol. 2010 Jun;69(6):578-92. doi: 10.1111/j.1365-2125.2010.03639.x. Review.

13.

The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men.

van de Giessen E, Booij J.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1507-11. doi: 10.1007/s00259-010-1424-2. Epub 2010 Mar 23.

14.

Dopamine transporter trafficking: rapid response on demand.

Chen R, Furman CA, Gnegy ME.

Future Neurol. 2010 Jan 1;5(1):123.

15.

Drug choice, spatial distribution, HIV risk, and HIV prevalence among injection drug users in St. Petersburg, Russia.

Kruse GR, Barbour R, Heimer R, Shaboltas AV, Toussova OV, Hoffman IF, Kozlov AP.

Harm Reduct J. 2009 Jul 31;6:22. doi: 10.1186/1477-7517-6-22.

16.

Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy.

Furman CA, Chen R, Guptaroy B, Zhang M, Holz RW, Gnegy M.

J Neurosci. 2009 Mar 11;29(10):3328-36. doi: 10.1523/JNEUROSCI.5386-08.2009.

17.

Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse.

Zhu J, Reith ME.

CNS Neurol Disord Drug Targets. 2008 Nov;7(5):393-409. Review.

18.

Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.

Ferris MJ, Mactutus CF, Booze RM.

Neurosci Biobehav Rev. 2008 Jul;32(5):883-909. doi: 10.1016/j.neubiorev.2008.01.004. Epub 2008 Mar 18. Review.

20.

Role of monoamine transporters in mediating psychostimulant effects.

Riddle EL, Fleckenstein AE, Hanson GR.

AAPS J. 2005 Dec 20;7(4):E847-51. Review.

Supplemental Content

Support Center